Lv-Jia Cheng1,2, Jian-Hui Chen1,2, Song-Yao Chen1,2, Zhe-Wei Wei1, Long Yu1,2, Shao-Pu Han1,2, Yu-Long He1, Zi-Hao Wu3, Chuang-Qi Chen4,5. 1. Division of Gastrointestinal Surgery Center, The First Affiliated Hospital of Sun Yat-Sen University, No. 58 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong Province, China. 2. Department of Colorectal Surgery, The First Affiliated Hospital of Sun Yat-sen University, No. 58 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong Province, China. 3. Department of Surgery, University of Missouri Hospitals and Clinics, MC 502, One Hospital Drive, Columbia, MO, 65212, USA. 4. Division of Gastrointestinal Surgery Center, The First Affiliated Hospital of Sun Yat-Sen University, No. 58 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong Province, China. chenchqi@mail.sysu.edu.cn. 5. Department of Colorectal Surgery, The First Affiliated Hospital of Sun Yat-sen University, No. 58 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong Province, China. chenchqi@mail.sysu.edu.cn.
Abstract
BACKGROUND: Rectal cancers have long been treated as a single-entity disease; however, whether the prognosis of high rectal cancer (inferior margin located 10.1 to 15.0 cm from the anal verge) differs from that of mid/low rectal cancer (0 to 10.0 cm) remains disputed. METHODS: Patients with stages I-III rectal adenocarcinomas undergoing curative-intent surgery were enrolled between 2007 and 2013 in this retrospective analysis. Exclusion criteria were neoadjuvant therapy or concurrent cancers. Propensity score matching and Cox regression analysis were performed to compare a 5-year overall and cancer-specific survival between patients with high and mid/low rectal cancer. RESULTS: Of 613 patients who met the inclusion criteria, 199 (32.5%) and 414 (67.5%) had high and mid/low rectal cancer, respectively. After propensity score matching (187 cases for each group), the high group showed a better overall survival (70.9 vs. 56.9%, p = 0.042) and cancer-specific survival (77.4 vs. 60.3%, p = 0.028) at 5 years compared with the mid/low group with stage III disease. However, high rectal cancer did not demonstrate prognostic superiority in stages I-II disease. Multivariate analysis identified high tumor location as an independent prognostic factor for cancer-specific survival (hazards ratio = 0.422, 95% confidence interval 0.226-0.786, p = 0.007) and overall survival (hazards ratio = 0.613, 95% confidence interval 0.379-0.991, p = 0.046). CONCLUSIONS: Patients with stage III high rectal adenocarcinoma demonstrated better overall and cancer-specific survival than those with mid/low type, and tumor location was an independent prognostic factor for patients with rectal carcinomas.
BACKGROUND:Rectal cancers have long been treated as a single-entity disease; however, whether the prognosis of high rectal cancer (inferior margin located 10.1 to 15.0 cm from the anal verge) differs from that of mid/low rectal cancer (0 to 10.0 cm) remains disputed. METHODS:Patients with stages I-III rectal adenocarcinomas undergoing curative-intent surgery were enrolled between 2007 and 2013 in this retrospective analysis. Exclusion criteria were neoadjuvant therapy or concurrent cancers. Propensity score matching and Cox regression analysis were performed to compare a 5-year overall and cancer-specific survival between patients with high and mid/low rectal cancer. RESULTS: Of 613 patients who met the inclusion criteria, 199 (32.5%) and 414 (67.5%) had high and mid/low rectal cancer, respectively. After propensity score matching (187 cases for each group), the high group showed a better overall survival (70.9 vs. 56.9%, p = 0.042) and cancer-specific survival (77.4 vs. 60.3%, p = 0.028) at 5 years compared with the mid/low group with stage III disease. However, high rectal cancer did not demonstrate prognostic superiority in stages I-II disease. Multivariate analysis identified high tumor location as an independent prognostic factor for cancer-specific survival (hazards ratio = 0.422, 95% confidence interval 0.226-0.786, p = 0.007) and overall survival (hazards ratio = 0.613, 95% confidence interval 0.379-0.991, p = 0.046). CONCLUSIONS:Patients with stage III high rectal adenocarcinoma demonstrated better overall and cancer-specific survival than those with mid/low type, and tumor location was an independent prognostic factor for patients with rectal carcinomas.
Authors: E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde Journal: N Engl J Med Date: 2001-08-30 Impact factor: 91.245
Authors: Sung Pil Hong; Byung So Min; Tae Il Kim; Jae Hee Cheon; Nam Kyu Kim; Hoguen Kim; Won Ho Kim Journal: Eur J Cancer Date: 2011-11-07 Impact factor: 9.162
Authors: Hyunsoon Cho; Angela B Mariotto; Bhupinder S Mann; Carrie N Klabunde; Eric J Feuer Journal: Am J Epidemiol Date: 2013-07-03 Impact factor: 4.897
Authors: Al B Benson; Deborah Schrag; Mark R Somerfield; Alfred M Cohen; Alvaro T Figueredo; Patrick J Flynn; Monika K Krzyzanowska; Jean Maroun; Pamela McAllister; Eric Van Cutsem; Melissa Brouwers; Manya Charette; Daniel G Haller Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: S M E Engelen; M Maas; M J Lahaye; J W A Leijtens; C L H van Berlo; R L H Jansen; S O Breukink; C H C Dejong; C J H van de Velde; R G H Beets-Tan; G L Beets Journal: Eur J Cancer Date: 2013-04-06 Impact factor: 9.162
Authors: Walid K Chatila; Jin K Kim; Henry Walch; Michael R Marco; Chin-Tung Chen; Fan Wu; Dana M Omer; Danny N Khalil; Karuna Ganesh; Xuan Qu; Anisha Luthra; Seo-Hyun Choi; Yu-Jui Ho; Ritika Kundra; Katharine I Groves; Oliver S Chow; Andrea Cercek; Martin R Weiser; Maria Widmar; Iris H Wei; Emmanouil P Pappou; Garrett M Nash; Philip B Paty; Qian Shi; Efsevia Vakiani; S Duygu Selcuklu; Mark T A Donoghue; David B Solit; Michael F Berger; Jinru Shia; Raphael Pelossof; Paul B Romesser; Rona Yaeger; J Joshua Smith; Nikolaus Schultz; Francisco Sanchez-Vega; Julio Garcia-Aguilar Journal: Nat Med Date: 2022-08-15 Impact factor: 87.241
Authors: Hong Yang; Zhendan Yao; Ming Cui; Jiadi Xing; Chenghai Zhang; Nan Zhang; Maoxing Liu; Kai Xu; Fei Tan; Xiangqian Su Journal: BMC Cancer Date: 2020-08-14 Impact factor: 4.430